Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Avalo Therapeutics is currently in the clinical stage of growth as a biotechnology company. The company is focused on developing treatments for immune dysregulation. With a strong pipeline of innovative products, Avalo is steadily advancing towards commercialization and expanding its reach in the biotech industry.
Avalo Therapeutics has achieved significant milestones in its journey. One key milestone is the development of AVTX-009, the company's lead asset targeting inflammatory diseases. Additionally, the inclusion of two other promising product candidates, quisovalimab and AVTX-008, showcases Avalo's commitment to addressing various medical needs. These advancements demonstrate Avalo's dedication to advancing cutting-edge therapies and making a difference in patient care.
Avalo Therapeutics has been involved in impactful case studies that demonstrate the efficacy of its treatments. These studies have shown promising results in treating immune dysregulation and inflammatory conditions. The company's focus on precision medicine and innovative biologics has led to positive outcomes in patient outcomes and disease management. Avalo's dedication to improving healthcare through research and development is evident in these case studies.
Key events in Avalo Therapeutics' journey include the initiation of the Phase 2 LOTUS Trial for AVTX-009, highlighting the company's progress in clinical research. Additionally, the corporate presentation in October 2024 showcases Avalo's transparency and commitment to communication with investors and stakeholders. The ongoing development of AVTX-009 and other product candidates underscores Avalo's dedication to driving advancements in biotechnology. Overall, these events reflect Avalo's growth trajectory and commitment to innovation.
-
Active
Health Care/Life Sciences
540 Gaither Road Suite 400 Rockville Maryland 20850 United States...
United States
20
Mitchell Chan (Independent Director)
June Sherie Almenoff (Independent Director)
Dino C. Miano (Senior Vice President-CMC & Technical Operations)
Christopher Sullivan (Chief Financial Officer)
18.05 M
$11.25
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDCAiDOOS Information Wiki provides comprehensive information about products, companies, and individuals.
-
Health Care/Life Sciences
540 Gaither Road Suite 400 Rockville Maryland 20850 United States...
United States
20+
18.05 M
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDC